Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Adam reports back from the nation’s biggest hematology conference on an early but promising gene therapy that could end up being a cure for sickle cell. Then, STAT biotech correspondent Meghana Keshavan joins us to break down the strange case of recently approved drug that has some patients up in arms. Then we give you the need-to-know on Moderna (MRNA) Therapeutics and what its history-making IPO means for the whole drug industry.